Company profile TXG
10x Genomics Inc
advancing human health requires a greater understanding of biology, and that understanding starts with the cell. we enable researchers to drive exponential progress in oncology, immunology, neuroscience, and more with novel single cell, spatial, and in situ tools that have been cited in over 3,000 publications and continually improved by our dedicated scientific team. our aim: ...to develop innovative instruments, reagents, and software that allow you to see your biological system at a resolution that matches its complexity.
Show More
After 39 days of this quarter the interest is at 212.0. Based on that we can calculate that during remaining 52 days it will total up to 495.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 225 | 442 96.4% QoQ | 561 26.9% QoQ | 461 -17.8% QoQ |
| 2020 | 465 106.7% YoY 0.9% QoQ | 388 -12.2% YoY -16.6% QoQ | 384 -31.6% YoY -1.0% QoQ | 296 -35.8% YoY -22.9% QoQ |
| 2021 | 376 -19.1% YoY 27.0% QoQ | 279 -28.1% YoY -25.8% QoQ | 298 -22.4% YoY 6.8% QoQ | 300 1.4% YoY 0.7% QoQ |
| 2022 | 488 29.8% YoY 62.7% QoQ | 511 83.2% YoY 4.7% QoQ | 474 59.1% YoY -7.2% QoQ | 435 45.0% YoY -8.2% QoQ |
| 2023 | 520 6.6% YoY 19.5% QoQ | 516 1.0% YoY -0.8% QoQ | 502 5.9% YoY -2.7% QoQ | 483 11.0% YoY -3.8% QoQ |
| 2024 | 212 -59.2% YoY -56.1% QoQ | - | - | - |
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
The average 5 years interest of 10x genomics -stock -ipo -share was 33.01 per week. The last year interest of 10x genomics -stock -ipo -share compared to the last 5 years has changed by 17.09%. The interest for 10x genomics -stock -ipo -share is trending. The last year interest is comparable to 5 years ago. It has changed only by 6.92%.
Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
After 39 days of this quarter the interest is at 82.0. Based on that we can calculate that during remaining 52 days it will total up to 191.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 137 | 65 -52.6% QoQ | 230 253.8% QoQ | 275 19.6% QoQ |
| 2020 | 210 53.3% YoY -23.6% QoQ | 102 56.9% YoY -51.4% QoQ | 124 -46.1% YoY 21.6% QoQ | 160 -41.8% YoY 29.0% QoQ |
| 2021 | 185 -11.9% YoY 15.6% QoQ | 61 -40.2% YoY -67.0% QoQ | 106 -14.5% YoY 73.8% QoQ | 223 39.4% YoY 110.4% QoQ |
| 2022 | 186 0.5% YoY -16.6% QoQ | 381 524.6% YoY 104.8% QoQ | 277 161.3% YoY -27.3% QoQ | 239 7.2% YoY -13.7% QoQ |
| 2023 | 246 32.3% YoY 2.9% QoQ | 240 -37.0% YoY -2.4% QoQ | 230 -17.0% YoY -4.2% QoQ | 231 -3.3% YoY 0.4% QoQ |
| 2024 | 82 -66.7% YoY -64.5% QoQ | - | - | - |
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
The average 5 years interest of 10x chromium was 15.29 per week. The last year interest of 10x chromium compared to the last 5 years has changed by 18.97%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 26.58%.
Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for TXG
Company name: 10x Genomics Inc
Sector: Professional, Scientific, and Technical Services
Company's websiteHyperchartsYahoo FinanceMarketWatchStockTwitsSEC FilingsSwaggyStocksLatest articles
2026-10-13T16:05:00-04:00
PR Newswire
10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 20262026-10-13T15:51:47.519691012Z
Analyst Upgrades
TD Cowen Maintains Hold on 10x Genomics, Raises Price Target to $702026-10-13T15:32:20.441480889Z
Analyst Upgrades
Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $702026-10-12T17:07:52.181644284Z
Analyst Upgrades
Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $1002026-10-07T13:23:45.123831247Z
Analyst Upgrades
Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $1102026-10-07T09:00:00-04:00
PR Newswire
10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers2026-09-29T16:28:30.708567349Z
Analyst Upgrades
Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $902026-09-29T09:01:00-04:00
PR Newswire
10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions2026-09-29T09:00:00-04:00
PR Newswire
10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands2026-09-28T15:58:45.515857965Z
Analyst Upgrades
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $802026-09-28T12:34:48.991331562Z
Analyst Upgrades
This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday2026-09-28T12:10:43.736623293Z
Analyst Upgrades
Argus Research Initiates Coverage On 10x Genomics with Buy Rating, Announces Price Target of $1102026-09-10T09:00:00-04:00
PR Newswire
Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research2026-09-09T17:58:53.644663753Z
Analyst Upgrades
UBS Maintains Neutral on 10x Genomics, Raises Price Target to $682026-09-01T12:00:35.652519549Z
Analyst Upgrades
RBC Capital Initiates Coverage On 10x Genomics with Sector Perform Rating, Announces Price Target of $70